SAKK 35/14 randomized trial of rituximab with or without ibrutinib for patients with untreated follicular lymphoma
Maria Cristina Pirosa, Marianne Brodtkorb, Sämi Schär, Björn E. Wahlin et autres
0 citationsBritish Journal of Haematology
Anastasios Stathis
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
569Publications signalées
8382Citations signalées
4Affiliations récentes
Institutions déclarées
Domaines associés
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia ResearchProtein Degradation and InhibitorsCutaneous lymphoproliferative disorders researchCAR-T cell therapy research
Publications récentes
Safety and preliminary efficacy results of a new micellar formulation of docetaxel in patients with metastatic castration-resistant prostate cancer - SAKK 67/20 trial
Ilaria Colombo, Pascale C. S. Rietveld, Stefanie Fischer, Stefania Merlo et autres
0 citationsCancer Chemotherapy and Pharmacology
IL-16 production is a mechanism of resistance to BTK inhibitors and R-CHOP in lymphomas
Alberto J. Arribas, Eleonora Cannas, Giulio Sartori, Francesca Guidetti et autres
6 citationsBlood
Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors: A multicenter phase Ib/IIa trial with expansion cohorts in melanoma and soft tissue sarcoma patients (SAKK 66/17).
Markus Joerger, Kira‐Lee Koster, Enrique Alejandre-Lafont, Patrick Knuesel et autres
0 citationsJournal of Clinical Oncology
Abstract 1848: IL-1-driven signaling promotes resistance to PI3K and BCL2 inhibitors in B-cell lymphoma preclinical models.
Alberto J. Arribas, Federica Fuzio, Eleonora Cannas, Michela Chiappa et autres
0 citationsCancer Research
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Laura Barnabei, Alberto J. Arribas, Luciano Cascione, Gabriela Forestieri et autres
0 citationsSSRN Electronic Journal
TLD-1, a Novel Liposomal Doxorubicin, in Patients with Solid Tumors: Comparative Pharmacokinetics and Final Results of a Multicenter Phase 1 Study (SAKK 65/16)
Marian Klose, Ilaria Colombo, Katrin Gobat, Kira‐Lee Koster et autres
1 citationClinical Pharmacokinetics
A retrospective analysis of phase I and phase I/II investigator-initiated clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK)
Kira‐Lee Koster, Ilaria Colombo, Stefanie Hayoz, Klaus Eckhardt et autres
0 citationsESMO Open
High-Throughput Screening Identifies PLK1 Inhibition as a Strategy to Potentiate BTK Blockade in Marginal Zone Lymphoma
Alex Zadro, Alberto J. Arribas, Michela Robusto, Stefania Vultaggio et autres
0 citationsbioRxiv (Cold Spring Harbor Laboratory)
Supplementary Table S4 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Timothy A. Yap, David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro et autres
0 citations
Supplementary Table S1 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Timothy A. Yap, David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro et autres
0 citations
Supplementary Figure S7 from Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects
Timothy A. Yap, David S.P. Tan, Anastasios Stathis, Geoffrey I. Shapiro et autres
0 citations
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.